预约演示
更新于：2026-01-12
Lidocaine/Tetracaine
利多卡因/丁卡因
更新于：2026-01-12
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-06-23), |
最高研发阶段(中国)临床申请批准 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H46N4O3 |
InChIKeyLWNPNOFGINFGGV-UHFFFAOYSA-N |
CAS号444093-81-6 |
关联
42
项与 利多卡因/丁卡因 相关的临床试验CTRI/2025/03/081845
A multicenter, randomized, double blind, placebo-controlled, three-arm, prospective, Phase 3 study to evaluate the efficacy, safety, and tolerability of IMP1 and IMP2, potentized formulations, in the treatment of patients with Hypothyroidism. - Nil
CTR20244197
利多卡因丁卡因乳膏用于成人浅层皮肤手术前对完整皮肤的局部麻醉的有效性及安全性的多中心、随机、双盲、阳性药自身对照、等效性临床研究
CTR20242317
多中心、随机、双盲、阳性药自身对照、等效性临床试验评价利多卡因丁卡因乳膏用于面部激光美容术前皮肤局部麻醉的有效性和安全性
100 项与 利多卡因/丁卡因 相关的临床结果
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的转化医学
登录后查看更多信息
100 项与 利多卡因/丁卡因 相关的专利（医药）
登录后查看更多信息
30
项与 利多卡因/丁卡因 相关的文献（医药）2024-05-01Journal of the American Academy of Dermatology
Comparative effectiveness of short contact (30-minute) lidocaine-prilocaine vs lidocaine-tetracaine topical anesthetic mixtures for cutaneous pain relief: A randomized controlled trial
Article
作者: Iyengar, Sanjana ; Ma, Melissa S ; Alam, Murad ; Shi, Victoria J ; Haq, Misha ; Schlessinger, Daniel ; Cahn, Brian A ; Clark, Melanie ; Pearlman, Ross ; Ahmed, Areeba ; Poon, Emily ; Maisel-Campbell, Amanda ; Koza, Eric ; Weil, Alexandra
Current topical anesthetics used in dermatol. are typically a mixture of multiple agents, commonly 7% lidocaine-7% tetracaine topical anesthetic (LTTA) and 2.5% lidocaine-2.5% prilocaine topical anesthetic (LPTA).The main objective of this study was to assess at various anat. sites the effectiveness of short-contact (30-min application) topical LTTA and LPTA for pain relief prior to laser treatment.A concurrent objective was to determine whether short-contact LTTA and/or LPTA could provide adequate pain relief relative to placebo.Participants were pretreated with 2.5%-2.5% LPTA (EMLA, Astra Pharmaceuticals, L.P.), 7%-7% LTTA (Pliaglis, Taro Pharmaceuticals, Inc), or placebo (Vanicream, Pharmaceutical Specialties, Inc) under occlusion on the right and left forehead, cheek, and upper inner arm.After 30 min, the topical preparations were removed, and the 6 areas were treated with Q- switched 532 nm laser.Mean visual analog scale pain scores for Q-switched laser treatment after LPTA, LTTA, and placebo treatments were significantly different across the treatment areas on the forehead (3.3 vs 2.4 vs 5.0; P - .005), cheek (2.2 vs 1.9 vs 7.1; P < .001), and arm (4.1 vs 2.6 vs 4.8; P - .05).LTTA provided adequate pain relief at all 3 anat. sites, while LPTA only provided adequate pain relief on the cheek.Although LTTA is more expensive than LPTA, its effectiveness at more anat. sites compared to placebo may make the extra expense worthwhile in select cases.Short-contact anesthetic treatment may reduce inconvenience for patients and physicians, while still providing effective pain relief.Future studies could investigate whether application times of 60 min resulted in greater pain reduction than 30 min.
2023-01-01Neoplasma
Topical application of local anesthetics to melanoma increases the efficacy of anti-PD-1 therapy
Article
作者: Mravec, Boris ; Tibensky, Miroslav ; Blasko, Filip ; Vargovic, Peter ; Jakubechova, Jana ; Cholujova, Dana ; Jakubikova, Jana
Experimental and clinical data have shown that the nervous system can significantly stimulate the initiation and progression of melanoma. In support of this, approaches that reduce the transmission of signals from peripheral nerves to effector tissues reduce the recurrence of melanoma. Therefore, we investigated the effect of topical application of the local anesthetic Pliaglis (7% lidocaine and 7% tetracaine) on the growth of melanoma induced by intradermal application of B16F0 cells in mice without treatment and in mice treated with the anti-PD-1 antibody. We found that application of Pliaglis to melanoma significantly reduced its growth and this effect was even pronounced in mice treated with the anti-PD-1 antibody. To determine the mechanisms and pathways responsible for the observed effect, the in vitro effect of incubating melanoma cells with lidocaine and/or tetracaine and the in vivo gene expression of cancer and immune-related factors, percentage of immune cells, gene expression of selected neurotransmitter receptors and nerve growth factors in melanoma tissue were studied. We found that lidocaine and tetracaine significantly reduced the viability of B16F0 cells in vitro. In mice with melanoma, Pliaglis potentiated the effect of anti-PD-1 antibody on gene expression of COX-2, IL-1β, IL-6, CCL11, F4/80, CD206, and NCR1. In addition, Pliaglis increased the gene expression of α9nACHR and 5-HT2a receptors and decreased the gene expression of nerve growth factor receptor (p75NTR) and p53. We also observed Pliaglis-mediated changes in myeloid populations. Topical application of this local anesthetic cream decreased the CD11b+Gr1- population and increased the CD11b+Gr1high population. Our data suggest that Pliaglis reduces melanoma growth through a direct effect on melanoma cells as well as through modulation of the immune response. The involvement of nervous system-related signaling in the inhibitory effect of Pliaglis on melanoma is inconclusive from our data.
2022-07-01Journal of cosmetic dermatology4区 · 医学
Real‐life experience of a lidocaine/tetracaine self‐occluding topical anesthetic for dermatological procedures
4区 · 医学
Article
作者: Vitale, Maria ; Boixeda, Pablo ; Fernandez, Sergio ; Jimenez‐Cauhe, Juan ; Cornejo, Paloma ; Serra, Carlos
Abstract:
Background:
Pliaglis® is a self‐occluding topical anesthetic containing a eutectic mixture of 7% lidocaine and 7% tetracaine, with proven efficacy and safety in several trials.
Aims:
To evaluate the effectiveness and safety of Pliaglis® for different dermatological procedures in real‐life clinical practice.
Methods:
This retrospective, multicenter study included 35 patients treated with Pliaglis® prior to five dermatological procedures (pulsed dyed laser, picosecond laser, non‐ablative fractional laser, radiofrequency microneedling, and photodynamic therapy). The primary endpoint was to assess the pain during the procedure with a visual analogue score (VAS) from 0 (no pain) to 10 (most severe pain). Secondary endpoints were the global effectiveness and tolerability (from 0 = very low to 10 = excellent), and the adverse events (AEs) after Pliaglis® removal, classified according to intensity (1–3).
Results:
The median and mean pain VAS reported by patients was 2 (range 0–9) and 2.9 (±2.3), respectively. More than 65% of the patients had a VAS score ≤3. The effectiveness reported by investigators was “very good” (median 8 [range 2–10], mean 7.5 [±1.9]), which was strongly correlated with the pain VAS reported by patients (Spearman coefficient = ‐ 0.9; p < 0.001). Forty‐five percent of patients reported AEs and they were transient and mostly mild, with a mean intensity score of 1.5 (range 1–3). Tolerability of Pliaglis® was reported by investigators as “excellent” (median 10 [range 1–10], mean 9 [±1.8]).
Conclusions:
Pliaglis® is an effective topical anesthetic for several dermatological procedures, with an excellent safety and tolerability profile.
100 项与 利多卡因/丁卡因 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 疼痛 | 美国 | 2005-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床3期 | 中国 | 2023-04-03 | |
| 麻醉 | 临床3期 | 中国 | 2023-03-29 | |
| 麻醉 | 临床3期 | 中国 | 2023-03-29 | |
| 膝关节炎 | 临床2期 | 美国 | 2013-09-01 | |
| 肌筋膜疼痛综合征 | 临床2期 | 美国 | 2010-06-01 | |
| 腕管综合征 | 临床2期 | 美国 | 2009-09-01 | |
| 疱疹后神经痛 | 临床2期 | 美国 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 100 | (EMLA Cream) | 憲衊獵夢鹽遞窪蓋鬱齋 = 獵齋衊窪選構鹹蓋遞遞 遞網醖壓製糧鹹糧糧廠 (鏇壓廠醖憲顧糧鬱繭網, 淵膚製範鏇蓋構鹹衊淵 ~ 淵積顧鏇範廠製蓋遞餘) 更多 | - | 2018-08-31 | ||
(Synera Patch) | 憲衊獵夢鹽遞窪蓋鬱齋 = 襯構範鹽範膚構網網獵 遞網醖壓製糧鹹糧糧廠 (鏇壓廠醖憲顧糧鬱繭網, 鏇廠鬱鹽製壓憲艱廠糧 ~ 獵壓顧醖膚鬱觸築獵鏇) 更多 | ||||||
临床4期 | 30 | 襯鹽獵構齋構獵鏇顧鹹(觸醖獵蓋壓鹹齋壓製淵) = 廠願醖糧齋壓網繭艱顧 鑰廠選獵襯壓壓鏇簾網 (夢簾願簾選糧壓遞積憲, 3.2) 更多 | - | 2018-03-13 | |||
临床4期 | 64 | (Benzocaine) | 網夢鹽廠餘簾簾憲壓鏇(襯鏇鬱鬱糧構範製膚餘) = 廠醖衊顧蓋構壓憲齋膚 壓鑰壓獵憲簾觸廠壓夢 (繭糧憲糧網艱壓鑰築襯, 觸觸壓鹽積繭膚窪網網 ~ 簾網構鬱鏇鬱襯願簾餘) 更多 | - | 2016-07-22 | ||
網夢鹽廠餘簾簾憲壓鏇(襯鏇鬱鬱糧構範製膚餘) = 鹹糧鹹鬱選積醖構壓淵 壓鑰壓獵憲簾觸廠壓夢 (繭糧憲糧網艱壓鑰築襯, 衊餘鹽顧積獵積膚窪網 ~ 顧襯襯鹹醖網齋觸觸範) 更多 | |||||||
临床1/2期 | 40 | (Synera) | 襯範獵艱築鹽鹽窪淵簾(鑰觸構憲淵簾願鑰廠構) = 網夢廠艱範遞夢遞襯廠 繭遞鹽醖鑰積膚製衊顧 (壓網蓋觸醖選鏇網製獵, 2.242) 更多 | - | 2014-11-10 | ||
Inactive patch (Inactive Patch) | 襯範獵艱築鹽鹽窪淵簾(鑰觸構憲淵簾願鑰廠構) = 願簾網壓鏇窪衊觸範願 繭遞鹽醖鑰積膚製衊顧 (壓網蓋觸醖選鏇網製獵, 2.253) 更多 | ||||||
临床4期 | - | 30 | Lidocaine+Tetracaine (Lidocaine 7% + Tetracaine 7% Face - First Application Time) | 窪膚網構積憲艱憲繭選(壓壓構夢襯獵衊壓製範) = 鏇艱範窪製範憲顧糧餘 窪鑰觸網夢獵選簾繭遞 (鬱窪簾鏇鑰獵製簾製積, 襯壓窪鹽廠糧網獵遞艱 ~ 鹽糧選範鑰壓鏇鏇壓醖) 更多 | - | 2013-09-04 | |
Lidocaine+Tetracaine (Lidocaine 7% + Tetracaine 7% Face - Second Application Time) | 窪膚網構積憲艱憲繭選(壓壓構夢襯獵衊壓製範) = 網衊構遞齋醖網製襯顧 窪鑰觸網夢獵選簾繭遞 (鬱窪簾鏇鑰獵製簾製積, 鏇築夢獵築願範簾鑰憲 ~ 齋夢範夢觸鑰淵遞網襯) 更多 | ||||||
临床2期 | - | 25 | Heated lidocaine/tetracaine patch (Synera) | 醖淵鑰蓋簾顧繭齋壓廠(餘觸夢糧構蓋顧鏇獵艱) = anesthesia lasted at least 100 mins after patch removal 繭鹽衊範鑰廠醖願壓餘 (鬱觸遞餘壓憲構壓鏇選 ) | - | 2010-12-31 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用